selected publications
-
The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62.
Cell reports.
2022
Academic Article
GET IT
Times cited: 12 -
Targeting Genome Stability in Melanoma-A New Approach to an Old Field.
International journal of molecular sciences.
2021
Review
GET IT
Times cited: 3 -
Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells.
Cancer management and research.
2020
Academic Article
GET IT
Times cited: 14 -
Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro.
International journal of molecular sciences.
2019
Academic Article
GET IT
Times cited: 11 -
17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes.
Apoptosis : an international journal on programmed cell death.
2019
Academic Article
GET IT
Times cited: 10 -
Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program.
Journal of oncology.
2019
Academic Article
GET IT
Times cited: 98 -
Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.
PloS one.
2017
Academic Article
GET IT
Times cited: 9 -
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.
Laboratory investigation; a journal of technical methods and pathology.
2017
Academic Article
GET IT
Times cited: 19